Lee T K, Chen Y C, Lien I N, Liu M C, Huang Z S
Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Republic of China.
Stroke. 1988 May;19(5):566-70. doi: 10.1161/01.str.19.5.566.
The purpose of our study was to investigate the effects of different doses of acetylsalicylic acid on platelet aggregation. Among inpatients of the National Taiwan University Hospital, 236 cases of completed stroke and seven cases of reversible ischemic neurologic deficit that were diagnosed by computed tomography of the brain and that had not ingested acetylsalicylic acid or acetylsalicylic acidlike drugs for greater than 2 weeks before admission were selected for this study. Thromboxane B2 and 6-keto-PGF1 alpha were measured by radioimmunoassay, threshold concentration of adenosine diphosphate was measured by Born's method, and circulating platelet aggregates were measured by the method of Wu and Hoak. Various single doses of acetylsalicylic acid (75, 300, or 600 mg) or 300 mg acetylsalicylic acid every 6 hours for four doses or one dose of 300 mg acetylsalicylic acid with 75 mg dipyridamole significantly suppressed the mean plasma thromboxane B2 concentrations and elevated the mean adenosine diphosphate threshold concentrations. Abnormal plasma thromboxane B2 concentrations, adenosine diphosphate threshold concentrations, or circulating platelet aggregate ratios were significantly normalized after administration of these regimens. The effects were not significantly different among treatment groups. Forty milligrams of acetylsalicylic acid seemed to have less platelet-inhibitory effect. A single dose of 75 mg acetylsalicylic acid significantly inhibited platelet hyperfunction and effectively corrected the abnormal plasma thromboxane B2 concentrations, adenosine diphosphate threshold concentrations, and circulating platelet aggregate ratios. Higher doses did not enhance the inhibitory effect. In addition, this single dose of acetylsalicylic acid did not significantly suppress plasma 6-keto-PGF1 alpha. We conclude that 75 mg acetylsalicylic acid per day is adequate to inhibit platelet hyperfunction.
我们研究的目的是调查不同剂量的乙酰水杨酸对血小板聚集的影响。在台湾大学医院的住院患者中，选取了236例经脑部计算机断层扫描诊断为完全性卒中以及7例可逆性缺血性神经功能缺损的患者，这些患者在入院前2周内未摄入乙酰水杨酸或类乙酰水杨酸药物。采用放射免疫分析法测定血栓素B2和6-酮-前列腺素F1α，采用Born法测定二磷酸腺苷的阈值浓度，采用Wu和Hoak法测定循环血小板聚集体。各种单剂量的乙酰水杨酸（75、300或600mg）或每6小时服用300mg乙酰水杨酸共四剂，或一剂300mg乙酰水杨酸与75mg双嘧达莫联用，均能显著抑制血浆血栓素B2的平均浓度，并提高二磷酸腺苷的平均阈值浓度。给予这些治疗方案后，血浆血栓素B2浓度、二磷酸腺苷阈值浓度或循环血小板聚集率异常均得到显著正常化。各治疗组之间的效果无显著差异。40mg乙酰水杨酸似乎对血小板的抑制作用较小。单剂量75mg乙酰水杨酸能显著抑制血小板功能亢进，并有效纠正血浆血栓素B2浓度、二磷酸腺苷阈值浓度和循环血小板聚集率的异常。更高剂量并未增强抑制作用。此外，这一单剂量的乙酰水杨酸并未显著抑制血浆6-酮-前列腺素F1α。我们得出结论，每天75mg乙酰水杨酸足以抑制血小板功能亢进。
